Sanofi/AstraZeneca’s Nirsevimab Is Set To Transform RSV Treatment In Infants

 
• By Brenda Sandburg

Sanofi executives discuss ongoing efforts to make the monoclonal antibody available for the next RSV season and the impact it will have as the first prophylactic treatment for all infants. An FDA advisory committee is expected to discuss the biologics license application at a yet-to-be announced meeting.

RSV infants
The biologics license application for the first RSV prophylaxis for all infants is under FDA review. • Source: Shutterstock

More from Interviews

More from Pink Sheet